BiotequeROCO:4107 +0.87%84 EBITDA Margin % is 42.00% as of Dec. 2025, which is 13% above its 10-year median of 37.30. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$129.03 (Modestly Undervalued). Among 815 Medical Devices & Instruments companies, Bioteque ranks better than 96.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioteque's EBITDA for the
three
months ended in Dec. 2025 was NT$238 Mil. Bioteque's Revenue for the
three
months ended in Dec. 2025 was NT$567 Mil. Therefore, Bioteque's EBITDA margin for the quarter that ended in Dec. 2025 was 42.00%.
Bioteque (ROCO:4107) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioteque EBITDA Margin % Related Terms
Bioteque EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioteque's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4107 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bioteque's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioteque EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioteque's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioteque (ROCO:4107) has a EBITDA Margin % of 42.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioteque and its competitors. This is 13% above median its historical median of 37.30. Over the past decade, Bioteque's EBITDA Margin % has ranged from 33.44 to 41.04. According to the industry distribution chart, Bioteque ranks #32 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 3.9%.
Is Bioteque's EBITDA Margin % too high?
Bioteque's current EBITDA Margin % of 42.00% is 13% above median its 10-year median of 37.30. Over the past 10 years, this metric has ranged from a low of 33.44 to a high of 41.04. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Bioteque's value of 42.00% is 462.2% above this industry median. Based on the distribution chart, Bioteque ranks #32 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioteque has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bioteque ranks #32 out of 815 companies for EBITDA Margin %. This places Bioteque in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Bioteque's value of 42.00% is 462.2% above this benchmark. Historically, Bioteque's own EBITDA Margin % has ranged from 33.44 to 41.04 over the past decade. While the company's 10-year median is 37.30 vs. the industry median of 7.47, Bioteque has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioteque's current EBITDA Margin % of 42.00% is 462.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioteque and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioteque's current EBITDA Margin % is 42.00%, which is 13% above median its own 10-year median of 37.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$129.03, compared to a current price of NT$116.50 — trading 9.7% below its estimated fair value. The current EBITDA Margin % is 42.00%, which is 13% above median its 10-year median of 37.30 and 462.2% above the Medical Devices & Instruments industry median of 7.47. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current EBITDA Margin % is 42.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioteque (ROCO:4107) Overvalued in 2026?
Based on GuruFocus' analysis, Bioteque stock appears to be undervalued.
The current stock price of NT$116.50 is trading 9.7% below its estimated GF Value™ of NT$129.03.
GuruFocus considers Bioteque to be Modestly Undervalued.
Key valuation signals for ROCO:4107:
EBITDA Margin %: 42.00% (13% above median its 10-year median of 37.30)
GF Value™: NT$129.03 vs. price of NT$116.50 (9.7% below fair value)
Industry Position: 462.2% above the Medical Devices & Instruments median (#32 of 815)
No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
84GF Score
Get the complete analysis for ROCO:4107
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4107 has been successfully added to your 
